Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

MASH-COVID (Cremer), 2021 NCT04399980

mavrilimumab (n=21) vs. placebo (n=19)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Mavrilimumab
Single intravenous infusion of Mavrilimumab 6mg/kg

Control treatment

Placebo

Concomitant medications included antiviral drugs relatedto COVID-19, corticosteroids, convalescent plasma, otherimmunosuppressive agents, and antimicrobial drugsrelated to non-COVID-19 infections.

Patients

COVID 19 hospitalized

Patients with documented COVID19 pneumonia defined as positive SARS-CoV2 test AND abnormalities/infiltrates on chest x-ray or computed tomography AND active fever or documented fever within 24-48 hours or ongoing anti-pyretic use to suppress fever, hypoxia (Room air SpO2 <92% or requirement for supplemental oxygen), increased serum inflammatory marker (CRP > 5 mg/dL), severity of disease warrants inpatient hospitalization. Patients were excluded if they required mechanical ventilation.

Method

Double-blind.

Multicenter, 7 hospitals in United States.

Remark

A trial of 60 patients was planned, but given slow enrolment, the study was stopped early toinform the natural history and potential treatment effect.